scholarly journals Positron emission tomography/computed tomography for optimized colon cancer staging and follow up

2013 ◽  
Vol 49 (2) ◽  
pp. 191-201 ◽  
Author(s):  
Bodil Elisabeth Engelmann ◽  
Annika Loft ◽  
Andreas Kjær ◽  
Hans Jørgen Nielsen ◽  
Anne Kiil Berthelsen ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Colon Cancer ◽  
Cancer Staging ◽  
Emission Tomography ◽  
Positron Emission

scholarly journals Positron emission tomography/computed tomography for optimized colon cancer staging and follow-up.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 408-408
Author(s):  
Bodil E. Engelmann ◽  
Annika Loft ◽  
Andreas Kjær ◽  
Hans J. Nielsen ◽  
Anne Kiil Berthelsen ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Colon Cancer ◽  
Cancer Staging ◽  
Emission Tomography ◽  
Positron Emission ◽  
Pet Ct ◽  
Primary Colon Cancer ◽  
Primary Colon

408 Background: Optimal management of colon cancer requires detailed assessment of extent of disease. Diagnostic accuracy of 18F-fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT) in primary colon cancer staging and for detection of recurrence was investigated. Methods: PET/CT for preoperative staging was performed on 66 prospectively included patients with primary colon cancer. Diagnostic accuracy for PET/CT and CT alone was analysed. Forty-two stage I-III colon cancer patients had PET/CT follow-up examinations every six months for two years. Serological levels of Tissue Inhibitor of Metalloproteinases (TIMP-1), Carcinoembryonic Antigen (CEA), and liberated domain I of urokinase Plasminogen Activator Receptor [uPAR(I)] and FDG-uptake related tumour gene expression were analysed. Results: Accuracy for T-, N- and M-staging by PET/CT were 82 % [95% Confidence Interval (CI) 70; 91], 66 % [CI 51; 78] and 89 % [CI 79; 96]; for CT 77 % [CI 64; 87], 60 % [CI 46; 73] and 69 % [CI 57; 80]. Cumulative relapse incidences for stage I – III colon cancer at 6, 12, 18 and 24 months were 7.1 % [CI 0; 14.9]; 14.3 % [CI 3.7; 24.9]; 19.0 % [CI 7.1; 30.9] and 21.4 % [CI 9.0; 33.8]. PET/CT diagnosed all relapses detected during the first two postoperative years. High preoperative TIMP-1 levels were associated with significant hazards towards both risk of recurrence and shorter overall survival. FDG-uptake in colon cancer showed significant correlation to hexokinase 2, the hypoxia marker carboanhydrase IX and the proliferation marker ki67. Conclusions: This study indicates PET/CT to be a valuable tool for staging and follow-up in colon cancer. TIMP-1 provided prognostic information potentially useful in selection of patients for intensive follow-up.

Positron Emission Tomography–Computed Tomography in Oesophageal Cancer Staging: A Tailored Approach

2014 ◽  
Vol 39 (4) ◽  
pp. 1000-1007 ◽  
Author(s):  
David M. Bunting ◽  
Wesley W. Lai ◽  
Richard G. Berrisford ◽  
Tim J. Wheatley ◽  
Brent Drake ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Oesophageal Cancer ◽  
Cancer Staging ◽  
Emission Tomography ◽  
Positron Emission ◽  
Tailored Approach

scholarly journals Computed Tomography Assessment of Cerebral Perfusion Using a Distributed Parameter Tracer Kinetics Model: Validation with H2(15)O Positron Emission Tomography Measurements and Initial Clinical Experience in Patients with Acute Stroke

2007 ◽  
Vol 28 (2) ◽  
pp. 402-411 ◽  
Author(s):  
Sotirios Bisdas ◽  
Frank Donnerstag ◽  
Georg Berding ◽  
Thomas J Vogl ◽  
Choon Hua Thng ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Acute Stroke ◽  
Pet Imaging ◽  
Perfusion Ct ◽  
Emission Tomography ◽  
Minor Stroke ◽  
Distributed Parameter ◽  
Positron Emission

We describe a distributed parameter (DP) model for tracer kinetic analysis in brain and validate the derived perfusion values with positron emission tomography (PET) scans. The proposed model is applied on actual clinical cases of hemispheric stroke. Nine patients with experienced transient ischaemic attack or minor stroke and a stenosis of the internal carotid artery were referred for computed tomography (CT) and PET imaging. The applicability of the DP model in clinical practice was tested in seven patients with acute stroke who received a baseline perfusion CT study and a noncontrast follow-up CT study after 2.4 ± 1.8 days. The mean blood flow ( F) value for all patients with carotid stenosis in the pooled data (54 regions of interest (ROIs)) was 37.9 ± 11.2 mL/min per 100 g in perfusion CT and 35.6 ± 9.8 mL/min per 100 g in perfusion PET imaging [ r = 0.77 ( P = 0.00)]. Regression analysis of the pooled ROIs for every patient revealed significant correlation between F values in seven patients [ r = 0.50 to 0.79 ( r2-values ranged from 0.45 to 0.79), (0.01 ≤ P ≤ 0.05)]. Parametric maps that corresponded to all physiologic parameters were generated for every perfusion CT in the patients with acute stroke using the DP model. The ischaemic area was better delineated in F, intravascular blood volume and lag time ( tlag) maps. The correlation coefficient comparing the visually outlined regions of abnormality between the tlag parametric map and the follow-up CT scans was 0.81 ( P = 0.003). In conclusion, DP physiological model using more realistic pharmacokinetics is feasible in dynamic contrast-enhanced CT of the brain in patients with acute and chronic cerebrovascular disease.

scholarly journals IMAGING IN ENDOCRINOLOGY: 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up

2015 ◽  
Vol 173 (3) ◽  
pp. R115-R130 ◽  
Author(s):  
Massimo Salvatori ◽  
Bernadette Biondi ◽  
Vittoria Rufini
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Emission Tomography ◽  
Whole Body ◽  
Clinical Indications ◽  
Positron Emission ◽  
Pet Ct ◽  
Fdg Pet Ct

In recent years, 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG-PET/CT) has emerged as an important tool for the postoperative management of patients with differentiated thyroid cancer (DTC) and it is widely used in selected clinical situations. The most valuable role that FDG-PET/CT plays in clinical practice is that it can be used to obtain prognostic information in patients with increasing thyroglobulin (Tg) levels and negative 131I whole-body scan post-thyroidectomy and radioiodine (RAI) ablation. FDG-PET/CT may also have a potential role in the initial staging and follow-up of high-risk patients with aggressive histological subtypes, in the identification of patients who are at the highest risk of disease-specific mortality, in the management of patients with RAI-refractory disease, in clinical trials of novel targeted therapies in patients with advanced metastatic disease, and in the evaluation of thyroid nodules with indeterminate fine-needle aspiration for cytology. However, several controversies remain to be resolved, namely: the cutoff value of Tg in the selection of DTC patients for FDG-PET/CT, whether FDG-PET/CT scanning should be performed under thyrotropin stimulation or suppression, and the clinical significance of thyroid FDG-PET/CT incidentalomas. The aim of the present article is to provide an overview of the data about the molecular basis for, clinical indications of, and controversies related to the use of FDG-PET/CT in patients with DTC.

Sign in / Sign up

Export Citation Format

Share Document